A Study to Investigate the Use of Benralizumab in Patients with Bullous Pemphigoid. - FJORD

Study identifier:D325AC00002

ClinicalTrials.gov identifier:NCT04612790

EudraCT identifier:2020-000287-32

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients with Bullous Pemphigoid (FJORD)

Medical condition

Bullous Pemphigoid

Phase

Phase 3

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

67

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 31 Mar 2021
Primary Completion Date: 26 Oct 2023
Study Completion Date: 26 Oct 2023

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria